Growth Hormone Secretagogue Response describes the body’s quantifiable physiological reaction to agents administered to stimulate the release of endogenous Growth Hormone (GH) from the anterior pituitary gland. Evaluating this response is a key metric in assessing the functional integrity of the somatotropic axis. A robust response indicates preserved pituitary sensitivity and hypothalamic signaling capacity.
Origin
The term is rooted in pharmacology and endocrinology, derived from ‘secretagogue,’ meaning a substance that promotes secretion, and the specific GH pathway. It is a technical assessment used to gauge the potential for therapeutic intervention targeting GH deficiency or decline. The evaluation focuses on the effectiveness of the signal transmission.
Mechanism
Secretagogues, such as Sermorelin or Ipamorelin, act by mimicking or potentiating the action of Growth Hormone Releasing Hormone (GHRH) or inhibiting somatostatin, the natural GH inhibitor. This interaction stimulates somatotroph cells in the pituitary to synthesize and release GH into the systemic circulation. Measuring the resulting plasma GH peak confirms the fidelity of this signaling cascade under stimulation.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.